Tags

Type your tag names separated by a space and hit enter

The efficacy and tolerability of iron protein succinylate in the treatment of iron-deficiency anemia in pregnancy.

Abstract

The aim of this study was to evaluate the efficacy and tolerability of iron protein succinylate in the treatment of iron-deficiency anemia in pregnancy. One hundred and thirty anemic pregnant women were studied. Inclusion criteria were iron-deficiency type of anemia, and hemoglobin levels below of 11.5, 10.9 and 10.3 g/dl for the three trimesters of pregnancy, respectively. Twenty-five women who presented pregnancy-related complications were excluded during treatment. The remaining 105 were treated with 1600-mg iron protein succinylate per os daily for a period of four months. A group of anemia-related clinical signs and symptoms, and hematological parameters were recorded at the beginning of treatment, as well as two and four months later. They included epidermis and mucosal paleness, skin and nail lesions, glossitis, heart pulse, sickness, anorexia, apathy, ataxia, polypnea, insomnia, nervousness, paresthesias and other neurological symptoms; the hematological parameters included Hgb, hct, RBCs, WBCs, MCV, MCH, MCHC, PLTs, serum Fe and ferritin. Possible side or adverse effects were considered during treatment. The majority of symptoms and signs of anemia were gradually improved. There was a statistically significant increase in the means of Hgb, hct, WBCs, MCV, MCH, PLTs and serum ferritin (p < 0.05). Anemia was effectively treated in 100/105 (95.2%) women, but not in five patients (4.8%) who displayed poor compliance to the therapeutic protocol. There were transient and mild side-effects in seven (6.6%) treated women, namely diarrhea, epigastralgia, vomiting, and nausea, which however, did not necessitate discontinuation of the therapeutic protocol. Iron protein succinylate is an effective and well tolerated treatment of iron-deficiency anemia in pregnancy.

Authors+Show Affiliations

,

Department of Obstetrics & Gynecology, University of Crete, Greece.

, , , ,

Source

MeSH

Adult
Anemia, Iron-Deficiency
Cohort Studies
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Gestational Age
Humans
Maximum Tolerated Dose
Metalloproteins
Pregnancy
Pregnancy Complications, Hematologic
Pregnancy Outcome
Probability
Prospective Studies
Risk Assessment
Severity of Illness Index
Statistics, Nonparametric
Succinates
Treatment Outcome

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

16108396

Citation

Sifakis, S, et al. "The Efficacy and Tolerability of Iron Protein Succinylate in the Treatment of Iron-deficiency Anemia in Pregnancy." Clinical and Experimental Obstetrics & Gynecology, vol. 32, no. 2, 2005, pp. 117-22.
Sifakis S, Angelakis E, Papadopoulou E, et al. The efficacy and tolerability of iron protein succinylate in the treatment of iron-deficiency anemia in pregnancy. Clin Exp Obstet Gynecol. 2005;32(2):117-22.
Sifakis, S., Angelakis, E., Papadopoulou, E., Stratoudakis, G., Fragouli, Y., & Koumantakis, E. (2005). The efficacy and tolerability of iron protein succinylate in the treatment of iron-deficiency anemia in pregnancy. Clinical and Experimental Obstetrics & Gynecology, 32(2), pp. 117-22.
Sifakis S, et al. The Efficacy and Tolerability of Iron Protein Succinylate in the Treatment of Iron-deficiency Anemia in Pregnancy. Clin Exp Obstet Gynecol. 2005;32(2):117-22. PubMed PMID: 16108396.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The efficacy and tolerability of iron protein succinylate in the treatment of iron-deficiency anemia in pregnancy. AU - Sifakis,S, AU - Angelakis,E, AU - Papadopoulou,E, AU - Stratoudakis,G, AU - Fragouli,Y, AU - Koumantakis,E, PY - 2005/8/20/pubmed PY - 2005/11/8/medline PY - 2005/8/20/entrez SP - 117 EP - 22 JF - Clinical and experimental obstetrics & gynecology JO - Clin Exp Obstet Gynecol VL - 32 IS - 2 N2 - The aim of this study was to evaluate the efficacy and tolerability of iron protein succinylate in the treatment of iron-deficiency anemia in pregnancy. One hundred and thirty anemic pregnant women were studied. Inclusion criteria were iron-deficiency type of anemia, and hemoglobin levels below of 11.5, 10.9 and 10.3 g/dl for the three trimesters of pregnancy, respectively. Twenty-five women who presented pregnancy-related complications were excluded during treatment. The remaining 105 were treated with 1600-mg iron protein succinylate per os daily for a period of four months. A group of anemia-related clinical signs and symptoms, and hematological parameters were recorded at the beginning of treatment, as well as two and four months later. They included epidermis and mucosal paleness, skin and nail lesions, glossitis, heart pulse, sickness, anorexia, apathy, ataxia, polypnea, insomnia, nervousness, paresthesias and other neurological symptoms; the hematological parameters included Hgb, hct, RBCs, WBCs, MCV, MCH, MCHC, PLTs, serum Fe and ferritin. Possible side or adverse effects were considered during treatment. The majority of symptoms and signs of anemia were gradually improved. There was a statistically significant increase in the means of Hgb, hct, WBCs, MCV, MCH, PLTs and serum ferritin (p < 0.05). Anemia was effectively treated in 100/105 (95.2%) women, but not in five patients (4.8%) who displayed poor compliance to the therapeutic protocol. There were transient and mild side-effects in seven (6.6%) treated women, namely diarrhea, epigastralgia, vomiting, and nausea, which however, did not necessitate discontinuation of the therapeutic protocol. Iron protein succinylate is an effective and well tolerated treatment of iron-deficiency anemia in pregnancy. SN - 0390-6663 UR - https://www.unboundmedicine.com/medline/citation/16108396/full_citation L2 - http://www.diseaseinfosearch.org/result/441 DB - PRIME DP - Unbound Medicine ER -